People of Hispanic origin constitute the largest minority population in the United. Although

the National Cholesterol Education Program Adult Treatment Panel III guidelines indicate that

lipid management in Hispanic patients should be the same as in non-Hispanic white patients,

evidence suggests that they are less likely to be aware of, or screened for, high cholesterol.1

Since Hispanic individuals have traditionally been underrepresented in clinical trials

employing lipid-lowering therapies, the safety and efficacy of statin lipid-lowering therapy in

Hispanic patients have not been well characterized.1

Therefore the STudy Assessing RousvaStatin in HIspanic Population (STARSHIP) was

undertaken to provide data on the effects of rosuvastatin and atorvastatin in a population of

hypercholesterolemic Hispanics patients.1

Reference:

1. Lloret, R et al.  Comparison of rosuvastatin versus atorvastatin in Hispanic-American patients with hypercholesterolemia (from the STARSHIP trial). American Journal of Cardiology. 2006;98:768-773.